title: Feasibility of administering zoledronic acid in palliative patients being cared for in the community: results of a pilot study.
abstract: Tumour-induced hypercalcemia (TIH) and pain from bone metastases are common complications of advanced malignancy and have a significant negative impact on quality of life. Many cancer patients in the advanced stages of their palliative illness prefer to avoid hospitalization and to receive their care in the community setting. This small open-label prospective pilot study explored the feasibility of administering zoledronic acid intravenously in the community setting (home and residential hospices). It enrolled a convenience sample of 12 patients with advanced cancer and TIH (n = 7), malignant bone pain (n = 3), or TIH and malignant bone pain (n = 2). The mean duration of infusion was 15 minutes (range: 14-30 minutes). The total nursing time required was 95 minutes, and the mean total cost, including nursing time, travel time, and drug costs was $708.97 per infusion. This cost was compared with costs for clodronate and pamidronate ($402.52 and $406.12 respectively). Calcium fell from a mean of 2.97 mmol/L on day 0 to 2.63 mmol/L on day 4 and to 2.54 mmol/L on day 10. Delirium resolved in 2 of 5 patients with TIH-associated delirium. Intravenous zoledronic acid administered in the community to palliative patients at the end of life is feasible and safe, and the short duration of infusion offers advantages to patients and nursing resources alike. The higher cost of zoledronic acid per infusion may be offset by the advantage of its short infusion time.
authors.affiliation: Division of Palliative Medicine, University of Calgary, Calgary, AB. hubert.marr@albertahealthservices.ca
authors.forename: H K
authors.initials: HK
authors.lastname: Marr
authors.forename: C R
authors.initials: CR
authors.lastname: Stiles
authors.forename: M A
authors.initials: MA
authors.lastname: Boyar
authors.forename: T C
authors.initials: TC
authors.lastname: Braun
authors.forename: N A
authors.initials: NA
authors.lastname: Hagen
authors.forename: C
authors.initials: C
authors.lastname: Janzen
authors.forename: L M
authors.initials: LM
authors.lastname: Whitten
authors.forename: J L
authors.initials: JL
authors.lastname: Pereira
references.citation: Br J Cancer. 2005 May 23;92(10):1869-76
references.pmid: 15870721
references.citation: Int J Geriatr Psychiatry. 1999 Nov;14(11):936-40
references.pmid: 10556864
references.citation: J Chemother. 2006 Apr;18(2):217-20
references.pmid: 16736892
references.citation: Arch Gerontol Geriatr. 2006 Sep-Oct;43(2):187-92
references.pmid: 16325938
references.citation: J Pain Symptom Manage. 1997 Jun;13(6):319-26
references.pmid: 9204651
references.citation: Drugs. 2004;64(11):1197-211
references.pmid: 15161327
references.citation: J Clin Oncol. 2001 Jan 15;19(2):558-67
references.pmid: 11208851
references.citation: Ann Oncol. 1997 Sep;8(9):915-6
references.pmid: 9358945
references.citation: Curr Med Res Opin. 2007 Jul;23(7):1575-82
references.pmid: 17559749
references.citation: Health Technol Assess. 2004;8(4):1-176
references.pmid: 14960258
references.citation: Cochrane Database Syst Rev. 2002;(2):CD002068
references.pmid: 12076438
references.citation: Support Care Cancer. 1996 Jan;4(1):31-3
references.pmid: 8771291
references.citation: J Palliat Med. 2007 Apr;10(2):352-8
references.pmid: 17472506
references.citation: Support Care Cancer. 2004 Jun;12(6):463-6
references.pmid: 15088136